Table 2.
Provider Knowledge
| N, % | |
|---|---|
| CM Cause | |
| *Fungus | 15, 75 |
| Bacteria, Virus, or TB | 5, 25 |
| CM Transmission | |
| *Airborne | 11, 55 |
| Blood, contact, sexual contact | 9, 45 |
| Who is susceptible to CM? | |
| Immunocompromised | 20, 100 |
| What is the length of CM maintenance treatment | |
| 1 month | 5, 25 |
| 6 months | 9, 45 |
| 1 year | 3, 15 |
| *CD4 ≥200 | 3, 15 |
| What CD4 is used to screen for CM? | |
| *<200 | 7, 35 |
| Other | 13, 65 |
| What diagnostic tests do you use for CM? | |
| Lumbar Puncture or CSF analysis | 9, 45 |
| India Ink | 4, 20 |
| CrAg test | 11, 55 |
| CBC/Blood Culture | 2, 10 |
| I don’t know | 2, 10 |
| What treatment do you give most often for CM? | |
| Ampho B | 8, 40 |
| Fluconazole | 7, 35 |
| Ampho B and fluconazole | 5, 35 |
| What do you need to diagnose CM more accurately? | |
| India Ink | 5, 25 |
| *CSF/Lumbar Puncture | 4, 20 |
| *CrAg Test | 3, 15 |
| *CSF Culture | 5, 25 |
| Blood Culture | 2, 10 |
| X-ray | 1, 5 |
| I Don’t know | 1, 5 |
| Availability of Amphotericin B | |
| Not available | 13, 65 |
| Sometimes available | 7, 35 |
*
Denotes correct answer